Pre-bid notice of UNFPA's upcoming Vasectomy Kit Bid
UNFPA
Pre-bid notice of UNFPA's upcoming Vasectomy Kit Bid
Pre-bid notice
Reference:
UNFPA/DNK/ITB/24/017
Beneficiary countries or territories:
Multiple destinations (see the Countries or territories tab)
Published on:
17-Sep-2024
Deadline on:
26-Oct-2024 00:00 (GMT 2.00)
Description
Dear All,
UNFPA (United Nations sexual and reproductive health agency - http://www.unfpa.org/) would like to call attention to the upcoming Vasectomy Kit Bid, which is planned to be launched within the next few weeks (end of September/early October). The new Blanket Purchase Agreements (BPAs) will be established based on the result of the tender and the BPAs will be valid for 3 years to serve the needs of UNFPA programmes and Third Party Procurement Clients.
We also recommend potential bidders to review the following useful links:
- Quality Assurance Policy: http://www.unfpa.org/quality-assurance, http://www.unfpa.org/resources/reproductive-health-medicines and http://apps.who.int/prequal/
- Introduction of how to become UNFPA’s suppliers, including relevant templates, code of conduct and eligibility: http://www.unfpa.org/suppliers
- Procurement Statistics (2019-2021): https://www.unfpa.org/resources/unfpa-procurement-statistics-2021,https://www.unfpa.org/resources/procurement-statistics-2020,https://www.unfpa.org/resources/procurement-statistics-2019.
We are looking forward to your participation in this Bid.
Best regards,
UNFPA SCMU
MARION DELPIETRO - delpietro@unfpa.org
51111602
-
Cytarabine
51111606
-
Hydroxycarbamide or hydroxyurea
51111610
-
Methotrexate
51111617
-
Gemcitabine
51111625
-
Azacitidine
51111629
-
Clofarabine
51111642
-
Irinotecan
51111650
-
Pemetrexed
51111659
-
Topotecan
51111704
-
Mitomycin
51111716
-
Rituximab
51111717
-
Trastuzumab
51111728
-
Cabazitaxel
51111731
-
Bevacizumab
51111733
-
Bleomycin
51111736
-
Cetuximab
51111739
-
Etoposide
51111740
-
Daunorubicin hydrochloride
51111742
-
Eribulin
51111746
-
Ipilimumab
51111758
-
Panitumumab
51111761
-
Ranibizumab
51111765
-
Trabectedin
51111766
-
Vinblastine
51111767
-
Vincristine
51111772
-
Vinorelbine
51111778
-
Alemtuzumab
51111779
-
Carfilzomib
51111780
-
Durvalumab
51111781
-
Olaparib
51111782
-
Obinutuzumab
51111783
-
Brentuximab vedotin
51111784
-
Atezolizumab
51111785
-
Pembrolizumab
51111786
-
Pertuzumab
51111802
-
Bicalutamide
51111803
-
Estramustine
51111805
-
Goserelin
51111815
-
Triptorelin
51111820
-
Letrozole
51111824
-
Exemestane
51111828
-
Cyproterone
51111830
-
Abiraterone
51111833
-
Axitinib
51111838
-
Bortezomib
51111842
-
Degarelix
51111855
-
Lanreotide
51111856
-
Lapatinib
51111862
-
Nilotinib
51111863
-
Octreotide
51111873
-
Tamoxifen
51111874
-
Tamoxifen citrate
51111875
-
Anastrozole
51111876
-
Leuprorelin
51111877
-
Enzalutamide
51111878
-
Goserelin acetate
51111901
-
Asparaginase
51111904
-
Paclitaxel
51112001
-
Capecitabine
51112002
-
Dasatinib
51112004
-
Gefitinib
51112005
-
Imatinib
51112006
-
Pazopanib
51112008
-
Sorafenib
51112010
-
Vandetanib
51112012
-
Afatinib
51112014
-
Erlotinib hydrochloride
51112015
-
Imatinib mesiate or mesylate
51112016
-
Sorafenib tosylate
51112017
-
Sunitinib malate
51112020
-
Ceritinib
51112021
-
Palbociclib
51112022
-
Ibrutinib
51112023
-
Ruxolitinib
51112026
-
Cabozantinib
51112027
-
Regorafenib
51112028
-
Nintedanib
51112029
-
Abemaciclib
51112030
-
Ribociclib
51112031
-
Lenvatinib
51112032
-
Crizotinib
51112033
-
Baricitinib
51112034
-
Osimertinib
51112035
-
Alectinib
51112037
-
Midostaurin
51112088
-
Acalabrutinib
51112301
-
Busulfan
51112402
-
Dacarbazine
51112503
-
Bendamustine
51112505
-
Chlorambucil
51112507
-
Cyclophosphamide
51112508
-
Bendamustine hydrochloride
51112510
-
Ifosfamide
51112513
-
Melphalan
51112601
-
Carmustine
51112701
-
Carboplatin
51112702
-
Cisplatin
51112705
-
Oxaliplatin
51112804
-
Raloxifene
51112901
-
Amifostine
51112902
-
Temozolomide
51113000
-
Alkylating agent amines
51113501
-
Pipobroman
51113502
-
Piposulfan
51113503
-
Venetoclax